pegaspargase
idelalisib
thioguanine
ponatinib
alvocidib
Elspar
asparaginase
venetoclax
axicabtagene ciloleucel
fludarabine
tafasitamab
antileukemia
acalabrutinib
antileukemic
lymphangiostatic
antilymphocyte
alemtuzumab
Leukeran
chlorambucil
chloraminophene
acute lymphoblastic leukemia
axicabtagene
antileprotic
tyrosine kinase inhibitor
lymphagogue
mogamulizumab
506U78
antilymphangiogenic
promyeloleukemia
lymphocytotoxic
EPOCH
immunocyte
leucocrit
pirtobrutinib
ofatumumab
homoharringtonine
lysocyte
olutasidenib
rituximab
lymphoblastoid
autolymphocyte
leukotoxigenic
hybridoma
acedapsone
ubenimex
afutuzumab
clofarabine
galiximab
leukotoxin
tazemetostat
prolymphangiogenic
lymphographical
lumiliximab
lymphosuppressive
antileukotriene
sialophorin
lymphohyperplasia
leukocytoid
gemtuzumab ozogamicin
immunotherapeutic
achroacytosis
lymphotoxin
antileukoprotease
lenzilumab
leukoblastic
leucoblastoma
lymphoblastic leukemia
erythroleukemia
lymphocytoma
loncastuximab tesirine
lymphodeplete
lymphosuppression
antileukocidin
acasunlimab
ibritumomab tiuxetan
thiotepa
piposulfan
Waldenström's macroglobulinemia
umbralisib
hematogone
lymphoepithelium
Castleman's disease
leukolysis
lymphoplasmocytic
resminostat
DLBCL
leukaemogenesis
biochemotherapy
mosunetuzumab
monalizumab
ivosidenib
leukemogenicity
lymphocytolytic
lympho-
talacotuzumab
chemoagent
nonlymphopenic
dapsone